Breaking News
FONT-SIZE Plus   Neg
Share SHARE

Ford Vehicles Probed For Stalling On Highway

RELATED NEWS
Trade F now with 

The National Highway Traffic Safety Administration (NHTSA) is investigating problems with stalling and/or surging engines in nearly 775,000 Ford passenger cars and SUVs. The government agency and Ford have received 1,500 complaints about the issue. One injury has been reported.

The vehicles affected by the investigation are the 2009 through 2011 models of Ford Escape and Mercury Mariner SUVs and Ford Fusion and Mercury Milan sedans.

According to the NHTSA, the engines do not quit but shift into one of three reduced-power "limp-home" modes. The sudden cut in power can feel to a driver as if the engine stalled.

"Depending on the condition of throttle control system malfunction, a driver may experience varying levels of reduced engine performance associated with three limp home modes. In two limp modes, reduced engine performance may maintain vehicle speeds above 20mph while the third is a limited limp home mode with engine speeds limited to approximately 900 RPM," said NHTSA.

No recall has been issued yet.

Click here to receive FREE breaking news email alerts for Ford Motor Co and others in your portfolio

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Editors Pick
A Thai company has bought iconic U.S. tuna brand Bumble Bee for $1.51 billion dollars. Thai Union Frozen Products Public Company Limited or TUF, the world's largest processor of shelf-stable tuna products snapped up Bumble Bee from private equity firm Lion Capital. Post Synergies, the transaction... Here is a list of interesting stocks to watch on December 19. The good news is you can skip this step. There is a next move that can make your life a lot easier. Our research team has already done the groundwork for you. All these stocks listed below and many more have been researched already, and... Shares of OvaScience Inc. (OVAS) have had a strong run in 2014, rising over 370 percent year-to-date. And that's indeed a very impressive return delivered by the fertility treatment company, which suffered a setback last year when it had to suspend a U.S. trial of its flagship fertility treatment due to regulatory concerns raised by the FDA.
comments powered by Disqus
FREE Newsletters, Analysis & Alerts

 

Stay informed with our FREE daily Newsletters and real-time breaking News Alerts. Sign up to receive the latest information on business news, health, technology, biotech, market analysis, currency trading and more.